Colorectal Cancer Screening at Younger Ages: A Multicutoff Analysis of FIT Performance [0.03%]
年轻年龄结直肠癌筛查：FIT性能的多重截止分析
Julia Hibbert,Teresa Seum,Michael Hoffmeister et al.
Julia Hibbert et al.
Background: Due to rising early-onset colorectal cancer (CRC) incidence, lowering the starting age for CRC screening is considered in many countries. However, data on diagnostic performance of fecal immunochemical tests (...
Neoadjuvant Bevacizumab and Chemoradiotherapy for Locally Advanced Rectal Cancer: Long-Term Outcomes of a Multicentre Study [0.03%]
贝伐单抗联合术前放化疗治疗局部晚期直肠癌的多中心研究长期结果分析
Ilaria Prata,Iris D Nagtegaal,Geke Hospers et al.
Ilaria Prata et al.
Background: Neoadjuvant treatment for locally advanced rectal cancer (LARC) evolves rapidly, and targeted agents could play a relevant role. Patients and ...
The Impact of Lesion Morphology and Resection Strategy on Curative Outcomes in Colorectal Malignant Polyps [0.03%]
colorectal恶性息肉的病变形态与切除方式对其治愈效果的影响
João C Gonçalves,Ana I Ferreira,Mariana Souto et al.
João C Gonçalves et al.
Background: Colorectal malignant polyps (MPs) appear benign endoscopically but display cancer cell invasion beyond the muscularis mucosae. Their recognition is challenging, as most lack overt signs of submucosal invasion ...
Comparing Quality of Life in Rectal Cancer Survivors Managed With Watch-and-Wait Versus Surgery [0.03%]
比较观察等待与手术治疗的直肠癌幸存者的生活质量
Sina Vatandoust,Luigi Sposato,David Wattchow et al.
Sina Vatandoust et al.
Background: A nonoperative (watch-and-wait) approach is increasingly accepted for patients with rectal cancer who achieve a complete clinical response to neoadjuvant treatment. This study aimed to investigate the effect o...
Resource Use and Costs of the Low-risk Arm of a Risk-stratified Colorectal Cancer Screening Approach Based on Previous Negative FIT Values: Comparative Analyses With the Standard Approach [0.03%]
基于既往阴性FIT结果分层的结直肠癌筛查方法低风险组的资源利用和费用：与传统策略对比分析
Andrea Buron,Merce Comas,Carmen Guirado-Fuentes et al.
Andrea Buron et al.
Background: Risk-stratified colorectal cancer (CRC) screening may improve benefit-risk ratios and alleviate colonoscopy demands. Utilizing previous faecal immunochemical tests (FIT) values below positivity thresholds is p...
Prognostic Value of Liver Metastases and KRAS Mutations in Patients With Metastatic Colorectal Cancer: A Pooled Analysis of Third-Line Placebo-Controlled Trials From the ARCAD CRC Database [0.03%]
III期临床试验数据库中转移性结直肠癌患者肝脏转移和KRAS突变的预后价值：来自法国ACCORD-CRC数据库的安慰剂对照试验Pooling分析结果
Thomas Samaille,Morteza Raeisi,Romain Cohen et al.
Thomas Samaille et al.
Background: KRAS mutations in metastatic colorectal cancer (mCRC) are a factor of poor prognosis, partly because of associated resistance to anti-EGFR therapies. Liver metastases (LM) were also described as a factor of po...
Dual CTLA-4/PD-1 Blockade Versus Anti-PD-1 in MSI-H Metastatic Colorectal Cancer: Early Survival Benefit and Exploratory Clinical Predictors [0.03%]
CTLA-4和PD-1抑制剂联合治疗与单用PD-1抑制剂治疗MSI-H转移性结直肠癌的早期生存益处及临床预测指标：一项探索性研究
Lea Jehanno,Julie Henriques,Thomas Samaille et al.
Lea Jehanno et al.
Introduction: Immune checkpoint inhibitors (ICI) are standard for MSI-H/dMMR metastatic colorectal cancer (mCRC). We compared their efficacy and sought subgroups deriving greater benefit from ICI combination. ...
Optimizing Systemic Therapy in Advanced Gastrointestinal Malignancies: Strategies to Minimize Toxicity and Maximize Tolerability [0.03%]
晚期胃肠恶性肿瘤系统治疗的优化：最小化毒性和最大化耐受性的策略
Sabrina Bulancea,Udhayvir S Grewal,Marta Wronska et al.
Sabrina Bulancea et al.
Advanced gastrointestinal cancers remain a major global health challenge, with rising incidence especially among younger populations. Systemic chemotherapy continues to be the mainstay of care for most patients, but balancing treatment bene...
Fruquintinib or Regorafenib? A Weighted Toxicity Score Analysis to Facilitate Better Discussions on Toxicity and Benefits in Later-line Colorectal Cancer Treatment [0.03%]
弗鲁奎替尼与瑞戈非尼？一种加权毒性评分分析，有助于更好地进行转移性结直肠癌后线治疗获益及毒性的讨论
Salvatore Corallo,Francesco Agustoni,Anna Pagani et al.
Salvatore Corallo et al.
Background: Regorafenib and fruquintinib are key treatment options for later-line therapy in metastatic colorectal cancer. In the absence of direct comparative studies, treatment selection frequently depends on safety pro...
Discordant Dynamics Between Absolute ctDNA and Tumor Fraction During Treatment Monitoring in Metastatic Colorectal Cancer: Evidence of a Dilution Phenomenon [0.03%]
绝经后转移性结直肠癌治疗期间绝对ctDNA和肿瘤突变分数动态不一致：ctDNA稀释现象的证据
Yuji Takayama,Kosuke Ichida,Taro Fukui et al.
Yuji Takayama et al.
Introduction: Circulating tumor DNA (ctDNA) is a promising biomarker for monitoring metastatic colorectal cancer. Tumor fraction, defined as the proportion of tumor-derived DNA within total circulating cell-free DNA (cfDN...